Animal Models for Francisella tularensis and Burkholderia Species: Scientific and Regulatory Gaps Toward Approval of Antibiotics Under the FDA Animal Rule

Veterinary Pathology

Volumn 50, Issue 5, 2013, Pages 877-892

  Stundick, M V ^a   Albrecht, M T ^a   Houchens, C R ^a   Smith, A Pierce ^a   Dreier, T M ^a   Larsen, J C ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

animal model; animal rule; antibiotic; BARDA; biodefense; Burkholderia; Francisella

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; LEVOFLOXACIN;

ANIMAL; ANIMAL MODEL; ANIMAL RULE; ARTICLE; BARDA; BIODEFENSE; BURKHOLDERIA; BURKHOLDERIA INFECTION; DISEASE MODEL; DRUG APPROVAL; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; FRANCISELLA; FRANCISELLA TULARENSIS; GOVERNMENT REGULATION; LEGAL ASPECT; METHODOLOGY; TULAREMIA; UNITED STATES;

ANIMAL MODEL; ANIMAL RULE; ANTIBIOTIC; BARDA; BIODEFENSE; BURKHOLDERIA; FRANCISELLA;

ANIMALS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA; BURKHOLDERIA INFECTIONS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG APPROVAL; FRANCISELLA TULARENSIS; GOVERNMENT REGULATION; LEVOFLOXACIN; TULAREMIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84883620777     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985813486812     Document Type: Article

References (120)

1. Amemiya K,Bush GV,DeShazer D, et al.Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.Infect Immun. 2002;70:2319-2325.
2. Amemiya K,Meyers JL,Deshazer D, et al.Detection of the host immune response to Burkholderia mallei heat-shock proteins GroEL and DnaK in a glanders patient and infected mice.Diagn Microbiol Infect Dis. 2007;59:137-147.
3. Amemiya K,Meyers JL,Trevino SR, et al.Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice.Vaccine. 2006;24:1413-1420.
4. Ancuta P,Pedron T,Girard R, et al.Inability of the Francisella tularensis lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins.Infect Immun. 1996;64:2041-2046.
5. Barnes JL,Ketheesan N.Route of infection in melioidosis.Emerg Infect Dis. 2005;11:638-639.
6. Baskerville A,Hambleton P.Pathogenesis and pathology of respiratory tularaemia in the rabbit.Br J Exp Pathol. 1976;57:339-347.
7. Baskerville A,Hambleton P,Dowsett AB.The pathology of untreated and antibiotic-treated experimental tularaemia in monkeys.Br J Exp Pathol. 1978;59:615-623.
8. Beisel WR.Neutrophile alkaline phosphatase changes in tularemia, sandfly fever, Q fever and noninfectious fevers.Blood. 1967;29:257-268.
9. Beisel WR,Bruton J,Anderson KD, et al.Adrenocortical responses during tularemia in human subjects.J Clin Endocrinol Metab. 1967;27:61-69.
10. Beisel WR,Sawyer WD,Ryll ED, et al.Metabolic effects of intracellular infections in man.Ann Intern Med. 1967;67:744-779.
11. Bondi SK,Goldberg JB.Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei.Expert Rev Vaccines. 2008;7:1357-1365.
12. Brett PJ,Deshazer D,Woods DE.Characterization of Burkholderia pseudomallei and Burkholderia pseudomallei-like strains.Epidemiol Infect. 1997;118:137-148.
13. Laboratory-acquired human glanders-Maryland, May 2000.MMWR Wkly. 2000;49:532-535.
14. Chantratita N,Rholl DA,Sim B, et al.Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei.Proc Natl Acad Sci U S A. 2011;108:17165-17170.
15. Conlan JW,Shen H,Golovliov I, et al.Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.Vaccine. 2010;28:1824-1831.
16. Conlan JW,Zhao X,Harris G, et al.Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis.Mol Immunol. 2008;45:2962-2969.
17. Currie BJ,Fisher DA,Howard DM, et al.The epidemiology of melioidosis in Australia and Papua New Guinea.Acta Trop. 2000;74:121-127.
18. Currie BJ,Jacups SP.Intensity of rainfall and severity of melioidosis, Australia.Emerg Infect Dis. 2003;9:1538-1542.
19. Day WC,Berendt RF.Experimental tularemia in Macaca mulatta: relationship of aerosol particle size to the infectivity of airborne Pasteurella tularensis.Infect Immun. 1972;5:77-82.
20. Dembek ZFMedical Aspects of Biological Warfare. Washington, DC: Borden Institute; 2007:.
21. DeShazer D,Brett PJ,Carlyon R, et al.Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene.J Bacteriol. 1997;179:2116-2125.
22. DeShazer D,Brett PJ,Woods DE.The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence.Mol Microbiol. 1998;30:1081-1100.
23. DeShazer D,Waag DM,Fritz DL, et al.Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant.Microb Pathog. 2001;30:253-269.
24. Downs CM,Buchele L,Edgar EP.Studies on pathogenesis and immunity in tularemia; the pathogenesis of tularemia in the white rat.J Immunol. 1949;63:117-133.
25. Duangsonk K,Gal D,Mayo M, et al.Use of a variable amplicon typing scheme reveals considerable variation in the accessory genomes of isolates of Burkholderia pseudomallei.J Clin Microbiol. 2006;44:1323-1334.
26. Ellis J,Oyston PC,Green M, et al.Tularemia.Clin Microbiol Rev. 2002;15:631-646.
27. Estes DM,Dow SW,Schweizer HP, et al.Present and future therapeutic strategies for melioidosis and glanders.Expert Rev Anti Infect Ther. 2010;8:325-338.
28. Feigin RD,Dangerfield HG.Whole blood amino acid changes following respiratory-acquired Pasteurella tularensis infection in man.J Infect Dis. 1967;117:346-351.
29. Foley JE,Nieto NC.Tularemia.Vet Microbiol. 2010;140:332-338.
30. Fritz DL,Vogel P,Brown DR, et al.Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei).Vet Pathol. 2000;37:626-636.
31. Fritz DL,Vogel P,Brown DR, et al.The hamster model of intraperitoneal Burkholderia mallei (glanders).Vet Pathol. 1999;36:276-291.
32. Galyov EE,Brett PJ,DeShazer D.Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis.Annu Rev Microbiol. 2010;64:495-517.
33. Goodyear A,Kellihan L,Bielefeldt-Ohmann H, et al.Protection from pneumonic infection with Burkholderia species by inhalational immunotherapy.Infect Immun. 2009;77:1579-1588.
34. Hambleton P,Baskerville A,Harris-Smith PW, et al.Changes in whole blood and serum components of grivet monkeys with experimental respiratory Francisella tularensis infection.Br J Exp Pathol. 1978;59:630-639.
35. Harland DN,Chu K,Haque A, et al.Identification of a LolC homologue in Burkholderia pseudomallei, a novel protective antigen for melioidosis.Infect Immun. 2007;75:4173-4180.
36. Hayden HS,Lim R,Brittnacher MJ, et al.Evolution of Burkholderia pseudomallei in recurrent melioidosis.PLoS One. 2012;7:e36507.
37. Hepburn MJ,Simpson AJ.Tularemia: current diagnosis and treatment options.Expert Rev Anti Infect Ther. 2008;6:231-240.
38. Hesselbrock W,Foshay L.The morphology of Bacterium tularense.J Bacteriol. 1945;49:209-231.
39. Hoppe I,Brenneke B,Rohde M, et al.Characterization of a murine model of melioidosis: comparison of different strains of mice.Infect Immun. 1999;67:2891-2900.
40. Howard K,Inglis TJ.Novel selective medium for isolation of Burkholderia pseudomallei.J Clin Microbiol. 2003;41:3312-3316.
41. US Food and Drug Administration. November 29, 2012 meeting of Anti-Infective Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm293600.htm. Accessed May 8, 2012.
42. US Food and Drug Administration. FDA approves raxibacumab to treat inhalational anthrax. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332341.htm. Accessed December 18, 2012.
43. Jeddeloh JA,Fritz DL,Waag DM, et al.Biodefense-driven murine model of pneumonic melioidosis.Infect Immun. 2003;71:584-587.
44. Judy BM,Whitlock GC,Torres AG, et al.Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to ceftazidime and levofloxacin.BMC Microbiol. 2009;9:88.
45. Kaufmann AF,Alexander AD,Allen MA, et al.Melioidosis in imported non-human primates.J Wildl Dis. 1970;6:211-219.
46. Ko WC,Cheung BM,Tang HJ, et al.Melioidosis outbreak after typhoon, southern Taiwan.Emerg Infect Dis. 2007;13:896-898.
47. Leakey AK,Ulett GC,Hirst RG.BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis.Microb Pathog. 1998;24:269-275.
48. Leelarasamee A.Burkholderia pseudomallei: the unbeatable foe?.Southeast Asian J Trop Med Public Health. 1998;29:410-415.
49. Leelarasamee A.Recent development in melioidosis.Curr Opin Infect Dis. 2004;17:131-136.
50. Lever MS,Nelson M,Ireland PI, et al.Experimental aerogenic Burkholderia mallei (glanders) infection in the BALB/c mouse.J Med Microbiol. 2003;52:1109-1115.
51. Lever MS,Nelson M,Stagg AJ, et al.Experimental acute respiratory Burkholderia pseudomallei infection in BALB/c mice.Int J Exp Pathol. 2009;90:16-25.
52. Limmathurotsakul D,Wongratanacheewin S,Teerawattanasook N, et al.Increasing incidence of human melioidosis in northeast Thailand.Am J Trop Med Hyg. 2010;82:1113-1117.
53. Lipsitz R,Garges S,Aurigemma R, et al.Consensus guidelines for treatment and post-exposure prophylaxis for infection with Burkholderia pseudomallei (melioidosis) and B. mallei (glanders): summary of the 2010 U.S. Department of Health and Human Services Burkholderia workshop, Townsville, Australia.Emerg Infect Dis. In press;:.
54. Liu B,Koo GC,Yap EH, et al.Model of differential susceptibility to mucosal Burkholderia pseudomallei infection.Infect Immun. 2002;70:504-511.
55. Lopez J,Copps J,Wilhelmsen C, et al.Characterization of experimental equine glanders.Microbes Infect. 2003;5:1125-1131.
56. Lyons CR,Wu TH.Animal models of Francisella tularensis infection.Ann N Y Acad Sci. 2007;1105:238-265.
57. Manzeniuk IN,Galina EA,Dorokhin VV, et al.Burkholderia mallei and B. pseudomallei, study of immuno- and pathogenesis of glanders and melioidosis, heterologous vaccines.Antibiot Khimioter. 1999;44:21-26.
58. Massey S,Johnston K,Mott TM, et al.In vivo bioluminescence imaging of Burkholderia mallei respiratory infection and treatment in the mouse model.Front Microbiol. 2011;2:174.
59. Matyas BT,Nieder HS,Telford SR III.Pneumonic tularemia on Martha's Vineyard: clinical, epidemiologic, and ecological characteristics.Ann N Y Acad Sci. 2007;1105:351-377.
60. McCrumb FR.Aerosol infection of man with Pasteurella tularensis.Bacteriol Rev. 1961;25:262-267.
61. Miller WR,Pannell L,Cravitz L, et al.Studies on certain biological characteristics of Malleomyces mallei and Malleomyces pseudomallei, II: virulence and infectivity for animals.J Bacteriol. 1948;55:127-135.
62. Moore RA,DeShazer D,Reckseidler S, et al.Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei.Antimicrob Agents Chemother. 1999;43:465-470.
63. Nandi T,Ong C,Singh AP, et al.A genomic survey of positive selection in Burkholderia pseudomallei provides insights into the evolution of accidental virulence.PLoS Pathog. 2010 6:e1000845.
64. Nelson M,Dean RE,Salguero FJ, et al.Development of an acute model of inhalational melioidosis in the common marmoset (Callithrix jacchus).Int J Exp Pathol. 2011;92:428-435.
65. Nelson M,Lever MS,Dean RE, et al.Bioavailability and efficacy of levofloxacin against Francisella tularensis in the common marmoset (Callithrix jacchus).Antimicrob Agents Chemother. 2010;54:3922-3926.
66. Nelson M,Lever MS,Dean RE, et al.Characterization of lethal inhalational infection with Francisella tularensis in the common marmoset (Callithrix jacchus).J Med Microbiol. 2010;59:1107-1113.
67. Nelson M,Lever MS,Savage VL, et al.Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus).Int J Exp Pathol. 2009;90:109-118.
68. Oyston PC,Griffiths R.Francisella virulence: significant advances, ongoing challenges and unmet needs.Expert Rev Vaccines. 2009;8:1575-1585.
69. Peacock SJ.Melioidosis.Curr Opin Infect Dis. 2006;19:421-428.
70. Peacock SJ,Schweizer HP,Dance DA, et al.Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei.Emerg Infect Dis. 2008;14:e2.
71. Pearson T,U'Ren JM,Schupp JM, et al.VNTR analysis of selected outbreaks of Burkholderia pseudomallei in Australia.Infect Genet Evol. 2007;7:416-423.
72. Price EP,Hornstra HM,Limmathurotsakul D, et al.Within-host evolution of Burkholderia pseudomallei in four cases of acute melioidosis.PLoS Pathog. 2010;6:e1000725.
73. Propst KL,Troyer RM,Kellihan LM, et al.Immunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infection.Antimicrob Agents Chemother. 2010;54:1785-1792.
74. Ray HJ,Chu P,Wu TH, et al.The Fischer 344 rat reflects human susceptibility to Francisella pulmonary challenge and provides a new platform for virulence and protection studies.PLoS One. 2010;5:e9952.
75. Raymond CR,Conlan JW.Differential susceptibility of Sprague-Dawley and Fischer 344 rats to infection by Francisella tularensis.Microb Pathog. 2009;46:231-234.
76. Reckseidler SL,DeShazer D,Sokol PA, et al.Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant.Infect Immun. 2001;69:34-44.
77. Reed DS,Smith L,Dunsmore T, et al.Pneumonic tularemia in rabbits resembles the human disease as illustrated by radiographic and hematological changes after infection.PLoS One. 2011;6:e24654.
78. Rowland CA,Lertmemongkolchai G,Bancroft A, et al.Critical role of type 1 cytokines in controlling initial infection with Burkholderia mallei.Infect Immun. 2006;74:5333-5340.
79. Rowland CA,Lever MS,Griffin KF, et al.Protective cellular responses to Burkholderia mallei infection.Microbes Infect. 2010;12:846-853.
80. Rozak DA,Gelhaus HC,Smith M, et al.CpG oligodeoxyribonucleotides protect mice from Burkholderia pseudomallei but not Francisella tularensis Schu S4 aerosols.J Immune Based Ther Vaccines. 2010;8:2.
81. Russell P,Eley SM,Ellis J, et al.Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders.J Antimicrob Chemother. 2000;45:813-818.
82. Sam IC,See KH,Puthucheary SD.Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.J Clin Microbiol. 2009;47:1556-1558.
83. Sarkar-Tyson M,Smither SJ,Harding SV, et al.Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders.Vaccine. 2009;27:4447-4451.
84. Saslaw S,Eigelsbach HT,Prior JA, et al.Tularemia vaccine study, II: respiratory challenge.Arch Intern Med. 1961;107:702-714.
85. Sawyer WD,Dangerfield HG,Hogge AL, et al.Antibiotic prophylaxis and therapy of airborne tularemia.Bacteriol Rev. 1966;30:542-550.
86. Schadewaldt H.Discovery of glanders bacillus.Dtsch Med Wochenschr. 1975;100:2292-2295.
87. Schell MA,Ulrich RL,Ribot WJ, et al.Type VI secretion is a major virulence determinant in Burkholderia mallei.Mol Microbiol. 2007;64:1466-1485.
88. Schricker RL.Pathogenesis of acute tularemia in the rabbit.Tech Manuscript. 1964;178:1-13.
89. Shambaugh GE III,Beisel WR.Insulin response during tularemia in man.Diabetes. 1967;16:369-376.
90. Shen H,Harris G,Chen W, et al.Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.PLoS One. 2010;5:e13349.
91. Sjostedt A.Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations.Ann N Y Acad Sci. 2007;1105:1-29.
92. Sprague LD,Neubauer H.Melioidosis in animals: a review on epizootiology, diagnosis and clinical presentation.J Vet Med B Infect Dis Vet Public Health. 2004;51:305-320.
93. Srinivasan A,Kraus CN,DeShazer D, et al.Glanders in a military research microbiologist.N Engl J Med. 2001;345:256-258.
94. Stanton AT,Fletcher W.Melioidosis and its relation to glanders.J Hyg (Lond). 1925;23:347-363.
95. Stuart BM,Pullen RL.Tularemia pneumonia: review of American literature and a report of 15 additional cases.Am J Med Sci. 1945;210:223-236.
96. Tan GY,Liu Y,Sivalingam SP, et al.Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice.J Med Microbiol. 2008;57:508-515.
97. Titball RW,Russell P,Cuccui J, et al.Burkholderia pseudomallei: animal models of infection.Trans R Soc Trop Med Hyg. 2008;102 (suppl 1): S111-S116.
98. Trevino SR,Permenter AR,England MJ, et al.Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge.Infect Immun. 2006;74:1958-1961.
99. Tumapa S,Holden MT,Vesaratchavest M, et al.Burkholderia pseudomallei genome plasticity associated with genomic island variation.BMC Genomics. 2008;9:190.
100. Twenhafel NA,Alves DA,Purcell BK.Pathology of inhalational Francisella tularensisspp. tularensis SCHU S4 infection in African green monkeys (Chlorocebus aethiops).Vet Pathol. 2009;46:698-706.
101. Twine S,Shen H,Harris G, et al.BALB/c mice, but not C57BL/6 mice immunized with a {up triangle, open}clpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses.Vaccine. 2012;30:3634-3645.
102. Twine SM,Shen H,Kelly JF, et al.Virulence comparison in mice of distinct isolates of type A Francisella tularensis.Microb Pathog. 2006;40:133-138.
103. Ulett GC,Ketheesan N,Hirst RG.Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei.Infect Immun. 2000;68:2034-2042.
104. Ulrich RL,Amemiya K,Waag DM, et al.Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice.Vaccine. 2005;23:1986-1992.
105. Ulrich RL,DeShazer D.Type III secretion: a virulence factor delivery system essential for the pathogenicity of Burkholderia mallei.Infect Immun. 2004;72:1150-1154.
106. Draft Guidance for Industry: Essential Elements to Address Efficacy Under the Animal Rule. Rockville, MD: FDA; 2009:.
107. Van Schaik E,Tom M,DeVinney R, et al.Development of novel animal infection models for the study of acute and chronic Burkholderia pseudomallei pulmonary infections.Microbes Infect. 2008;10:1291-1299.
108. Van Zandt KE,Tuanyok A,Gelhaus HC, et al.A literature-based system for selecting Burkholderia pseudomallei strain panels for animal model testing under the FDA animal rule. 10th ASM Biodefense and Emerging Diseases Research Meeting; Washington, DC;.
109. Van Zandt KE,Tuanyok A,Keim PS, et al.An objective approach for Burkholderia pseudomallei strain selection as challenge material for medical countermeasures efficacy testing.Front Cell Infect Microbiol. 2012;2:120.
110. Waag DM,DeShazer DBiological Weapons Defense: Infectious Diseases and Counterbioterrorism. Lindler LELebeda FJKorch GW, ed. Totowa, NJ: Humana Press; 2004:209-237.
111. Waag DM,McCluskie MJ,Zhang N, et al.A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei.Infect Immun. 2006;74:1944-1948.
112. Warawa JM.Evaluation of surrogate animal models of melioidosis.Front Microbiol. 2010;1:141.
113. Waterer GW,Robertson H.Bioterrorism for the respiratory physician.Respirology. 2009;14:5-11.
114. White NJ.Melioidosis.Lancet. 2003;361:1715-1722.
115. Whitlock GC,Estes DM,Torres AG.Glanders: off to the races with Burkholderia mallei.FEMS Microbiol Lett. 2007;277:115-122.
116. Whitlock GC,Robida MD,Judy BM, et al.Protective antigens against glanders identified by expression library immunization.Front Microbiol. 2011;2:227.
117. Whitlock GC,Valbuena GA,Popov VL, et al.Burkholderia mallei cellular interactions in a respiratory cell model.J Med Microbiol. 2009;58:554-562.
118. Wiersinga WJ,van der Poll T,White NJ, et al.Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei.Nat Rev Microbiol. 2006;4:272-282.
119. Wikraiphat C,Charoensap J,Utaisincharoen P, et al.Comparative in vivo and in vitro analyses of putative virulence factors of Burkholderia pseudomallei using lipopolysaccharide, capsule and flagellin mutants.FEMS Immunol Med Microbiol. 2009;56:253-259.
120. Yeager JJ,Facemire P,Dabisch PA, et al.Natural history of inhalation melioidosis in rhesus macaques (Macaca mulatta) and African green monkeys (Chlorocebus aethiops).Infect Immun. 2012;80:3332-3340.